New U.S. Appln. S.N. 10/534,988 AMENDMENT PATENT

IN THE CLAIMS:

please rewrite claim 16 as shown below in the detailed listing of all claims which are, or were, in the application:

Claims 1-10 (canceled).

- 11. (Previously presented) A method for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or an animal, wherein an effective amount of a pharmaceutically acceptable agent or salt thereof being able to acidify cell cytoplasm is admixed with a carrier capable of adjusting the pH of the composition to a pH range of from 6.1 to 7.0.
- 12. (Previously presented) The method of claim 11 wherein the agent is an acid having its dissociation constant in a range of from 6.7 to 7.4.
- 13. (Previously presented) The method of claim 12, wherein said dissociation constant is in a range of from 6.9 to 7.3

New U.S. Appln. S.N. 10/534,988 AMENDMENT PATENT

- 14. (Previously presented) The method of claim 13, wherein said dissociation constant is about 7.0.
- 15. (Previously presented) The method of claim 11, wherein said agent is cis-urocanic acid and wherein the carrier is able to adjust the pH of the composition to 6.5 to 7.0.
- 16. (Currently amended) A method of for treatment or prevention of a disease or disorder curable by immunosuppression, comprising administering to a person or animal in need of said treatment thereof a pharmaceutical composition produced by the method of claim 11 comprising a pharmaceutically acceptable agent or salt thereof capable of acidifying cell cytoplasm.

wherein an effective amount of said agent is administered in an essentially non-dissociated form to said person or animal, and wherein said agent is mixed with a carrier to adjust the pH of said composition to a pH range of 6.1 to 7.0.

17. (Previously presented) The method of claim 16, wherein the disease or disorder is a member of the group consisting of a local

New U.S. Appln. S.N. 10/534,988 AMENDMENT PATENT

inflammatory disease, a systemic inflammatory disease, an autoimmune disease and an allergic condition.

- 18. (Previously presented) The method of claim 17 wherein the disease or disorder is a local or systemic inflammatory reaction.
- 19. (Previously presented) The method of claim 18, wherein said reaction involves activation of cells of innate immune system.
- 20. (Previously presented) The method of claim 19, wherein said reaction is a member of the group consisting of contact hypersensitivity reactions, delayed type hypersensitivity reactions, acute graft rejection, psoriasis, dermatitis, periodontitis, mastitis, and vasculitis.
- 21. (Previously presented) The method of claim 16, wherein the agent is administered systemically or locally.
- 22. (Previously presented) The method of claim 21, where said agent is administered topically.

New U.S. Appln. S.N. 10/534,988 AMENDMENT

PATENT

- 23. (Previously presented) A pharmaceutical composition comprising as active agent a pharmaceutically acceptable agent or salt thereof being able to acidify the cell cytoplasm, in combination with a pharmaceutically acceptable carrier, which carrier essentially prevents the agent from dissociating at extracellular pH values and wherein the carrier is able to keep the pH of the composition in a range of from 6.1 to 7.0.
- 24. (Previously presented) The composition of claim 23 wherein said agent is an acid having a dissociation constant in a range of from 6.7 to 7.4.
- 25. (Previously presented) The composition of claim 24, wherein said dissociation constant is in a range of from 6.9 to 7.3.
- 26. (Previously presented) The composition of claim 25, wherein dissociation constant is about 7.0.
- 27. (Previously presented) The composition of claim 23, wherein said agent is cis-urocanic acid and wherein the carrier is able to keep the pH of the composition in a range of from 6.5 to 7.0.